BR112022010419A2 - Tratamento de hipoparatireoidismo - Google Patents
Tratamento de hipoparatireoidismoInfo
- Publication number
- BR112022010419A2 BR112022010419A2 BR112022010419A BR112022010419A BR112022010419A2 BR 112022010419 A2 BR112022010419 A2 BR 112022010419A2 BR 112022010419 A BR112022010419 A BR 112022010419A BR 112022010419 A BR112022010419 A BR 112022010419A BR 112022010419 A2 BR112022010419 A2 BR 112022010419A2
- Authority
- BR
- Brazil
- Prior art keywords
- hypoparathyroidism
- treatment
- pth compound
- patient
- titration
- Prior art date
Links
- 208000000038 Hypoparathyroidism Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000004448 titration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
TRATAMENTO DE HIPOPARATIREOIDISMO. A presente invenção refere-se a um composto de PTH para uso no tratamento de hipoparatireoidismo, em que composto administrações uma vez ao dia do composto de PTH a um paciente e titulação do paciente fora do padrão de cuidado dentro de quatro semanas contadas a partir de quando a primeira dose do composto de PTH foi administrada.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20151350 | 2020-01-13 | ||
EP20192565 | 2020-08-25 | ||
EP20216065 | 2020-12-21 | ||
PCT/EP2021/050460 WO2021144249A1 (en) | 2020-01-13 | 2021-01-12 | Hypoparathyroidism treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022010419A2 true BR112022010419A2 (pt) | 2022-08-23 |
Family
ID=74187267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022010419A BR112022010419A2 (pt) | 2020-01-13 | 2021-01-12 | Tratamento de hipoparatireoidismo |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230042670A1 (pt) |
EP (1) | EP4090357A1 (pt) |
JP (1) | JP2023510790A (pt) |
KR (1) | KR20220128390A (pt) |
CN (1) | CN115003320A (pt) |
AU (1) | AU2021208398A1 (pt) |
BR (1) | BR112022010419A2 (pt) |
CA (1) | CA3161101A1 (pt) |
IL (1) | IL294357A (pt) |
MX (1) | MX2022007371A (pt) |
WO (1) | WO2021144249A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2747316C2 (ru) | 2016-03-01 | 2021-05-04 | Асцендис Фарма Боун Дизизис А/С | Пролекарства pth |
JP7085535B2 (ja) | 2016-09-29 | 2022-06-16 | アセンディス ファーマ ボーン ディジージズ エー/エス | ピーク対トラフ比が小さいpth化合物 |
EP4275677A3 (en) | 2016-09-29 | 2024-01-10 | Ascendis Pharma Bone Diseases A/S | Dosage regimen for a controlled-release pth compound |
KR20240082355A (ko) * | 2021-09-22 | 2024-06-10 | 아센디스 파마 본 디지즈 에이/에스 | 장시간 작용형 pth 화합물 치료 |
WO2024094673A1 (en) * | 2022-11-02 | 2024-05-10 | Ascendis Pharma Bone Diseases A/S | Pth treatment regimen comprising two pth compounds |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
ES2512499T3 (es) | 2003-04-08 | 2014-10-24 | Yeda Research And Development Co., Ltd. | Fármacos pegilados reversibles |
US7690003B2 (en) | 2003-08-29 | 2010-03-30 | Fuller Jeffrey C | System and method for increasing data throughput using thread scheduling |
BRPI0414539B8 (pt) | 2003-09-19 | 2021-05-25 | Novo Nordisk As | composto, composição farmacêutica, e, uso de um composto |
CA2824093C (en) | 2004-03-23 | 2016-10-25 | Complex Biosystems Gmbh | Polymeric prodrug with a self-immolative linker |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
WO2008034122A2 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
PL2173890T3 (pl) | 2007-06-21 | 2011-07-29 | Univ Muenchen Tech | Białka czynne biologicznie o zwiększonej stabilności in vivo i (lub) in vitro |
JP2010533202A (ja) | 2007-07-11 | 2010-10-21 | エンゾン ファーマシューティカルズ,インコーポレーテッド | 多置換芳香族部分を含むポリマー性薬剤送達システム |
US8906847B2 (en) | 2008-02-01 | 2014-12-09 | Ascendis Pharma A/S | Prodrug comprising a drug linker conjugate |
EP2288261A4 (en) | 2008-05-23 | 2013-09-25 | Enzon Pharmaceuticals Inc | POLYMER SYSTEMS CONTAINING INTRA-CELLULAR RELEASE DISULFID LINKERS FOR THE DISPOSAL OF OLIGONUCLEOTIDES |
EP2459227B1 (en) | 2009-07-31 | 2021-03-17 | Ascendis Pharma A/S | Prodrugs containing an aromatic amine connected by an amide bond to a carrier |
EP2519228A4 (en) | 2009-12-31 | 2013-06-19 | Enzon Pharmaceuticals Inc | POLYMER CONJUGATES FROM AN AROMATIC AMINE WITH COMPOUNDS WITH A CLEANER UREA CONTAINER |
US9561285B2 (en) | 2010-01-22 | 2017-02-07 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
EP2525829A1 (en) | 2010-01-22 | 2012-11-28 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
EP2525830B1 (en) | 2010-01-22 | 2016-05-11 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
WO2011123813A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
CN103025164B (zh) | 2010-05-05 | 2017-03-08 | 普罗林科斯有限责任公司 | 从固体支撑物中药物的控制释放 |
CN103025165B (zh) | 2010-05-05 | 2016-06-08 | 普罗林科斯有限责任公司 | 自大分子共轭物的控释 |
CN103002906B (zh) * | 2010-05-13 | 2017-12-29 | 总医院有限公司 | 甲状旁腺激素类似物及其应用 |
PL2571510T3 (pl) | 2010-05-21 | 2019-03-29 | Xl-Protein Gmbh | Biosyntetyczne polipeptydy prolinowo/alaninowe o strukturze kłębka statystycznego i ich zastosowania |
WO2012002047A1 (ja) | 2010-06-30 | 2012-01-05 | Necソフト株式会社 | 属性判定方法、属性判定装置、プログラム、記録媒体および属性判定システム |
EP2741744A1 (en) | 2011-08-12 | 2014-06-18 | Ascendis Pharma A/S | Carrier-linked prodrugs having reversible carboxylic ester linkages |
EP2741782B1 (en) | 2011-08-12 | 2020-05-06 | Ascendis Pharma A/S | Protein carrier-linked prodrugs |
CA2843503C (en) | 2011-08-12 | 2020-12-22 | Ulrich Hersel | Polymeric hyperbranched carrier-linked prodrugs |
CN103857413A (zh) | 2011-08-12 | 2014-06-11 | 阿森迪斯药物股份有限公司 | 载体连接的曲罗尼尔前药 |
WO2013036857A1 (en) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
US20150087688A1 (en) | 2012-04-25 | 2015-03-26 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
EP2908845A1 (en) | 2012-10-17 | 2015-08-26 | Novo Nordisk Health Care AG | Fatty acid acylated amino acids for growth hormone delivery |
US20200354428A9 (en) * | 2013-06-23 | 2020-11-12 | Wisconsin Alumni Research Foundation | Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles |
CA2955569C (en) | 2014-08-06 | 2023-02-14 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
EP3518982A1 (en) * | 2016-09-29 | 2019-08-07 | Ascendis Pharma Bone Diseases A/S | Incremental dose finding in controlled-release pth compounds |
JP7085535B2 (ja) | 2016-09-29 | 2022-06-16 | アセンディス ファーマ ボーン ディジージズ エー/エス | ピーク対トラフ比が小さいpth化合物 |
US20210196801A1 (en) * | 2018-05-18 | 2021-07-01 | Ascendis Pharma Bone Diseases A/S | Starting Dose of PTH Conjugates |
EP3946460A4 (en) | 2019-04-05 | 2023-03-29 | Prolynx LLC | IMPROVED CONJUGATION LINKERS |
-
2021
- 2021-01-12 MX MX2022007371A patent/MX2022007371A/es unknown
- 2021-01-12 IL IL294357A patent/IL294357A/en unknown
- 2021-01-12 EP EP21700696.4A patent/EP4090357A1/en active Pending
- 2021-01-12 CN CN202180009185.0A patent/CN115003320A/zh active Pending
- 2021-01-12 KR KR1020227027792A patent/KR20220128390A/ko unknown
- 2021-01-12 US US17/783,640 patent/US20230042670A1/en active Pending
- 2021-01-12 BR BR112022010419A patent/BR112022010419A2/pt unknown
- 2021-01-12 AU AU2021208398A patent/AU2021208398A1/en active Pending
- 2021-01-12 JP JP2022542344A patent/JP2023510790A/ja active Pending
- 2021-01-12 CA CA3161101A patent/CA3161101A1/en active Pending
- 2021-01-12 WO PCT/EP2021/050460 patent/WO2021144249A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN115003320A (zh) | 2022-09-02 |
US20230042670A1 (en) | 2023-02-09 |
KR20220128390A (ko) | 2022-09-20 |
JP2023510790A (ja) | 2023-03-15 |
WO2021144249A1 (en) | 2021-07-22 |
MX2022007371A (es) | 2022-07-12 |
IL294357A (en) | 2022-08-01 |
AU2021208398A1 (en) | 2022-06-09 |
CA3161101A1 (en) | 2021-07-22 |
EP4090357A1 (en) | 2022-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022010419A2 (pt) | Tratamento de hipoparatireoidismo | |
MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
EP4272818A3 (en) | Thrombolytic agent for the treatment of thromboembolism | |
BR112015029918A2 (pt) | uso de alta dose de pridopidina para tratar a doença de huntington | |
MX2016011975A (es) | Metodos para reducir el riesgo cardiovascular. | |
RU2017134443A (ru) | Способ лечения с применением традипитанта | |
CL2021001810A1 (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
BR112021024886A2 (pt) | Métodos de tratar a doença de fabry em pacientes com insuficiência renal | |
RU2017120184A (ru) | Лекарства для замедления течения болезни паркинсона | |
BR112022025141A2 (pt) | Fabricação, formulação e dosagem de apraglutida | |
PH12015502655A1 (en) | Method | |
MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
BR112023020093A2 (pt) | Conjugado anticorpo-fármaco, incluindo anticorpo contra cldn18.2 humano, e uso do mesmo | |
WO2022170134A3 (en) | Dosing protocols for administering deuterated arachidonic acid or a prodrug thereof | |
BRPI0716929A8 (pt) | tratamento de esclerose múltipla com campath-1h | |
BR112018007399A2 (pt) | composição, método de tratamento, kit de partes e forma de dosagem | |
EA202191063A1 (ru) | Новая дозированная форма | |
BR112018008835A8 (pt) | composição farmacêutica oral, composição farmacêutica de liberação pulsátil oral, método para tratar uma condição de doença que requer terapia com fumarato de dimetila e método para tratar esclerose múltipla | |
MX2022009776A (es) | Tratamiento de la colangitis biliar primaria con elafibranor. | |
CA3199014A1 (en) | Combination therapy for the treatment of a liver disease | |
JOP20220104A1 (ar) | نظام تجريع لعوامل مضادة لـ dll3 | |
BR112022003419A2 (pt) | Forma de dosagem oral sólida compreendendo naproxeno e vitamina b12 | |
AU2020360413A8 (en) | Methods of treating conditions related to the S1P1 receptor | |
CR20200616A (es) | Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión | |
BR112018017167A2 (pt) | titulação de cebranopadol |